Anti-Insulin Receptor Antibodies in the Pathology and Therapy of Diabetes Mellitus
- 1 February 2021
- journal article
- review article
- Published by Bentham Science Publishers Ltd. in Current Diabetes Reviews
- Vol. 17 (2) , 198-206
Abstract
Diabetes mellitus (DM) is recognized as the most common and the world’s fastest-growing chronic disease with severe complications leading to increased mortality. Many strategies exist for the management of DM and its control, including treatment with insulin and insulin analogs, oral hypoglycemic therapy such as insulin secretion stimulators and insulin sensitizers, and diet and physical training. Over the years, many types of drugs and molecules with an interesting pharmacological diversity have been developed and proposed for their anti-diabetic potential. Such molecules target diverse key receptors, enzymes, and regulatory/signaling proteins known to be directly or indirectly involved in the pathophysiology of DM. Among them, insulin receptor (IR) is undoubtedly the target of choice for its central role in insulin-mediated glucose homeostasis and its utilization by the major insulin-sensitive tissues such as skeletal muscles, adipose tissue, and the liver. In this review, we focus on the implication of antibodies targeting IR in the pathology of DM as well as the recent advances in the development of IR antibodies as promising anti-diabetic drugs. The challenge still entails development of more powerful, highly selective, and safer anti-diabetic drugs.Keywords
Funding Information
- United Arab Emirates University (31S305)
This publication has 78 references indexed in Scilit:
- Selective Insulin Receptor Modulators (SIRM): A New Class of Antidiabetes Drugs?Diabetes, 2012
- A Fully Human, Allosteric Monoclonal Antibody That Activates the Insulin Receptor and Improves Glycemic ControlDiabetes, 2012
- Mechanisms for Insulin Resistance: Common Threads and Missing LinksCell, 2012
- Identification of a Molecular Activator for Insulin Receptor with Potent Anti-diabetic EffectsJournal of Biological Chemistry, 2011
- A novel hydroxyfuroic acid compound as an insulin receptor activator – structure and activity relationship of a prenylindole moiety to insulin receptor activationJournal of Biomedical Science, 2009
- The Barrier of Hypoglycemia in DiabetesDiabetes, 2008
- Minimizing Hypoglycemia While Maintaining Glycemic Control in DiabetesDiabetes, 2008
- Insulin-mimetic and insulin-sensitizing activities of a pentacyclic triterpenoid insulin receptor activatorBiochemical Journal, 2007
- Critical nodes in signalling pathways: insights into insulin actionNature Reviews Molecular Cell Biology, 2006
- Insulin signalling and the regulation of glucose and lipid metabolismNature, 2001